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Abstract
Background: This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy
for children with autism spectrum disorders ages 3-8 years.
Methods: Phase 1 involved 65 children who received one round of DMSA (3 days). Participants
who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase
2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds
of either DMSA or placebo.
Results: DMSA greatly increased the excretion of lead, substantially increased excretion of tin and
bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten.
There was some increase in urinary excretion of essential minerals, especially potassium and
chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione
in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease
in inflammation.
Conclusion: Overall, DMSA therapy seems to be reasonably safe, effective in removing several
toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in
normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and
platelets. Additional rounds increased excretion of toxic metals.
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Background
Autism is a severe developmental disorder which involves
social withdrawal, communication deficits, and stereo-
typic/repetitive behaviors. The cause(s) of autism are
unknown, but both genetic and environmental factors
have been implicated. One environmental factor that has
received significant attention is the body burden of mer-
cury and other toxic metals.
Heavy metal toxicity can occur from either a high expo-
sure or a decreased ability to excrete heavy metals, with
the latter case seeming to be the primary issue in autism.
The primary mechanism for excreting mercury and some
other toxic metals from the body involves binding to glu-
tathione and then being excreted in the bile [1]. Infants
are especially vulnerable to metal poisoning because they
are poor excretors due to low production of glutathione
[2], and because they are usually on all-milk diets, which
decreased mercury excretion by a factor of three in a study
of rats [3].
Infants with autism are even more vulnerable to mercury
and other heavy metals, because their glutathione levels
are much lower than those of typical children [4-6] and a
higher fraction of their glutathione is oxidized [4,5]. Also,
four studies have found that children with autism had
much higher usage of oral antibiotics than typical chil-
dren [7-10]. High oral antibiotic usage is concerning
because previous rat studies found that oral antibiotics
resulted in a near-total loss of the ability to excrete mer-
cury [3,11]. The reason appears to be that normal gut
anaerobes are able to convert methylmercury (which is
rapidly absorbed) into inorganic mercury (which is
poorly absorbed and hence mostly excreted). In contrast,
most strains of yeast and E. coli carry out the reverse reac-
tion, namely the methylation of inorganic mercury to
methylmercury [12]. So, high oral antibiotic use leads to
a loss of normal gut flora and an increase in yeast and E.
coli, resulting in a loss of ability to demethylate methylm-
ercury and an increased methylation of inorganic mer-
cury, ultimately resulting in decreased excretion and
increased uptake of mercury.
A decreased ability to excrete mercury is consistent with a
study [13] which found that children with autism had
only 1/8 the normal amount of mercury in their baby hair
compared to typical infants, even though both groups had
a similar exposure to the major sources of mercury (mater-
nal seafood, mercury dental amalgams, and thimerosal in
vaccines). There was also a significant inverse correlation
in the severity of autism and the level of mercury in the
hair, suggesting that the children with the weakest ability
to excrete mercury developed the most severe symptoms.
These results together suggest a decreased ability to excrete
mercury, resulting in a higher body burden. A replication
study [10] also found that children with autism tended to
have lower levels of mercury in their baby hair than did
typical infants. A recent study [14] of children ages 1-5
years found lower levels of lead, cadmium, and arsenic in
the hair of children with autism, suggesting a decreased
ability to excrete those metals; there was a similar trend
for mercury, but it was not statistically significant in those
older children.
There have also been studies of the level of mercury in the
hair and blood of older children with autism. These stud-
ies are of limited relevance because mercury has a half-life
of only several weeks in the blood, so they do not reflect
levels in early infancy when autism developed. One study
in the US found elevated levels of mercury and other toxic
metals in the blood [6]. A study in Hong Kong found a
possible difference in blood levels (p = 0.056) but not in
hair [15]. However, a re-analysis of their data found an
abnormal ratio of mercury in blood to mercury in hair,
suggesting an excretion problem [16]. One study in the US
did not find any difference in the level of mercury in the
hair of older children (ages 3-15 years) with autism vs.
controls [17].
A decreased ability to excrete mercury should result in a
higher body burden, and that was demonstrated in a
study which investigated the effect of giving DMSA
(dimercaptosuccinic acid) to 221 children with autism
compared to 18 controls [18]. They found that the chil-
dren with autism excreted 3.1 times as much mercury into
their urine (which is where DMSA is excreted), p < 0.0002,
but lead and cadmium levels were not significantly differ-
ent. Similarly, a small study [9] found that children with
autism had a 2× higher level of mercury in their baby teeth
compared to typical children. DMSA provocation testing
is probably a measure of both recent and older exposures,
whereas baby teeth are a measure of pre-natal and infan-
tile exposure.
A previous study [8] investigated possible factors affecting
heavy metal exposure in the medical history of children
with autism vs. controls. Four exposures were found to be
statistically different in children with autism spectrum dis-
orders (ASD) (n = 53) vs. controls (n = 48), including
higher maternal seafood consumption (RI = 2.7, p =
0.02); higher otitis media-related antibiotic use (RI = 2.5,
p = 0.0001); more eating/licking paint (p = 0.04), and
more pica (30% vs 2%, p = 0.0002). The ASD children
also had more immediate adverse reactions to vaccina-
tions (RI = 2.5, p = 0.002). The dental histories did not
reveal major differences, although there was a trend that
placement or removal of mercury fillings during preg-
nancy was more common in the mothers of children with
ASD than the controls (R.I. = 7.0, p = 0.08).BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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There have been many epidemiological studies of the pos-
sible link between thimerosal-containing vaccines and
autism since it was discovered in 1999 that the amount of
thimerosal in US childhood vaccines was far in excess of
FDA and EPA guidelines. Many studies by one group
reported a significant link [19-29], while 5 studies by
other groups failed to establish a link, [30-34], and one
study was inconclusive [35]. So, the link of autism to
thimerosal remains controversial.
A review article by Bernard et al. [36] reported that all of
the major symptoms of infantile autism are also com-
monly observed in infantile mercury poisoning, including
mental symptoms (language deficits, stereotypic behav-
iors, social withdrawal) and physical symptoms (gastroin-
testinal problems, sleep problems, low muscle tone, and
excessive salivation). A review by Nelson and Bauman
[37] disputes the Bernard et al. [36] paper, and argues that
the symptoms and neuropathology of autism are distinct
from mercury poisoning. However, the Toxicological Pro-
file of Mercury published by the US Agency for Toxic Sub-
stances and Disease Registry [38] states that infantile
exposure to mercury can result in neurological damage,
mental retardation, incoordination, muscle weakness, sei-
zures, and inability to speak, which are similar to the
symptoms of autism.
One study [39] found elevated urinary precoproporphy-
rins in children with autism (n = 106) vs. controls (n =
107), which is indicative of the effect of mercury on heme
synthesis. They found that those levels decreased signifi-
cantly after several months of DMSA therapy. Two smaller
studies [40,41] also found that children with autism had
higher levels of coproporphyrins than did controls, and
the children with autism had higher levels than the chil-
dren with PDD/NOS or Asperger's. One of the studies [41]
also found elevations in precoproporphyrins. Both stud-
ies found that children with autism who had undergone
chelation therapy had less elevation in their coproporphy-
rin levels. Another study [42] found that the level of mer-
cury-related porphyrins (coproporphyrin and
precoporphyrin) had a significant correlation with their
severity of autism as rated by the Childhood Autism Rat-
ing Scale (CARS). A recent report [43] found that the use
of DMSA could improve the learning, attention, and
arousal regulation of lead-exposed animals. However,
that same paper also found that high-dose administration
of DMSA could cause lasting cognitive damage in rats that
were not lead exposed, so DMSA should only be used
when lead or similar toxic metals are present.
Overall, there is a substantial body of research that sug-
gests mercury and other toxic metals could be involved in
the etiology of some cases of autism, although the autism-
thimerosal link remains controversial. There is also more
general evidence to suggest that lead, mercury, and other
toxins can impair child development at levels commonly
encountered by most of the US population [44]. There is
some evidence to suggest that the use of DMSA therapy to
remove toxic metals may be helpful in normalizing the
porphyrin-heme pathway, and possibly helpful in
improving some of the symptoms of autism.
The purpose of this paper is to evaluate the safety and effi-
cacy of DMSA therapy on children with autism spectrum
disorders (ASD), focusing on medical effects. The effects
of DMSA on behavior are discussed in the following paper
[45]. Also, this study found a high correlation of the sever-
ity of autism with the urinary excretion of toxic metals,
and the results are reported in another paper [46]. DMSA
is FDA-approved for the treatment of lead poisoning in
children as young as 2 years, and this study investigated its
use for an off-label application, namely treating children
with ASD who have evidence of significant heavy metal
exposure (based on urinary excretion after DMSA chal-
lenge). DMSA preferentially binds to lead, but can also
increase the excretion of several other toxic metals
(including mercury) to a lesser extent. Other agents, such
as DMPS, have a stronger affinity for mercury, but they are
not FDA-approved for human use, so it was decided to
begin an initial detoxification study with DMSA.
The specific objectives of this study include:
1) Evaluating the effect of DMSA therapy on children with
ASD, including effect on excretion of toxic metals, excre-
tion of essential minerals, level of glutathione, blood
chemistry, complete blood count (CBC), and symptoms
of autism.
2) Investigate possible correlations of the severity of
autism with urinary excretion of toxic metals and initial
level of glutathione.
Methods
The study was designed with one screening round (9
doses over 3 days) of DMSA in Phase 1, followed by a ran-
domized, double-blind, placebo-controlled study of 6
additional rounds (see Figure 1). The purpose of the
screening round was to only allow participants with high
excretion of toxic metals into phase 2. However, as dis-
cussed below, the single screening round of DMSA had an
unexpectedly dramatic effect on improving abnormal glu-
tathione and platelet levels, and that effect lasted until the
end of phase 2, so that phase 2 was not a placebo-control-
led investigation. Instead, it appears best to interpret this
study as a comparison of the effect of 1 round of DMSA
(and 6 rounds of placebo) vs. 7 rounds of DMSA. In dis-
cussing these two groups below, we will refer to them as
the "1 round" group and the "7 round" group.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
Page 4 of 22
(page number not for citation purposes)
Participant Selection
This study was conducted with the approval of the Human
Subjects Institutional Review Board of Southwest College
of Naturopathic Medicine. All parents and (where possi-
ble) children signed informed consent/assent forms.
The criteria for Phase One were:
1) Children with autism spectrum disorder, diagnosed by
a psychiatrist, psychologist, or developmental pediatri-
cian
2) Age 3-8 years
3) No mercury amalgam dental fillings
4) No previous use of DMSA or other prescription chela-
tors
5) No anemia or currently being treated for anemia due to
low iron.
6) No known allergies to DMSA
7) No liver or kidney disease
8) Children are well-hydrated (receiving adequate daily
intake of water)
The criteria for Phase Two were:
1) Excretion of high amounts of toxic metals in phase
one (defined below)
2) Normal liver function (serum transaminases ALT
and AST), normal renal function (although low creat-
inine was allowed), and complete blood cell count
was not below the normal reference range.
3) No changes in medication, supplements, diet, or
behavioral interventions during the study.
4) At least a two-month history of taking a multi-vita-
min/mineral supplement with at least the RDA of zinc,
and continuing to take that during Phase Two.
5) Continue to stay well-hydrated (receive adequate
daily intake of water).
The characteristics of the participants are given in Table 1.
All participants were Arizona residents.
Methodology
Phase One
1) Each child first received a physical examination to
determine that he/she was in sufficiently good health to
participate in the study.
2) A blood draw was conducted to test for blood chemis-
try (including kidney and liver function) and Complete
Blood Count (CBC), and Red Blood Cell (RBC) glutath-
ione. If liver and renal function were normal and CBCs
were not below the normal range, then the child was eli-
gible to participate in Phase 1.
3) Each parent filled out an initial Autism Treatment Eval-
uation Checklist (ATEC) questionnaire and Heavy Metal
Exposure Questionnaire.
4) Parents collected a baseline first-morning urine sample.
5) Parents began daily administration of a lotion that con-
tained glutathione or placebo, administered in a rand-
omized, double-blind fashion. It was administered 1×/
day, after bath on clean skin, with the child rubbing it on.
Glutathione was administered to half the children to see
if it affected their excretion of toxic metals and their levels
of toxic metals.
6) After 7 days of "glutathione" lotion, all children
received oral DMSA. The dosage was 10 mg/kg-dose, 3×/
day, for 3 days. The DMSA was compounded individually
for each child from pharmaceutical grade DMSA (over
99% pure) supplied by Spectrum Chemical. Parents col-
lected all urine for approximately 8 hours after the first
dose and for approximately 8 hours after the 9th dose.
Children were encouraged to urinate prior to taking the 1st
and 9th dose, but compliance was not required.
Study design Figure 1
Study design. Both groups of participants received a single 
challenge round of oral DMSA; those excreting significant 
heavy metals continued on to Phase 2, and received addi-
tional 6 additional rounds of DMSA or placebo.
Children with ASD
Randomized in double-blind manner
Topical 
Glutathione
Placebo
cream
One round
of oral DMSA
(9 doses)
(n=33 completed)
One round
of oral DMSA
(9 doses)
(n=31 completed)
low-excretors
of metals  
low-excretors
of metals   Metal
excretors
Metal
excretors
Subsequent
Rounds of
DMSA
(n=26 completed)
Subsequent
Rounds of
Placebo
(n=15 completed)
Phase
One
Phase
TwoBMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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7) Urine samples were frozen and shipped to Doctor's
Data Laboratories (St. Charles, IL) for measuring excretion
of toxic and essential minerals. Children with high excre-
tion of toxic metals (arbitrarily defined as above Doctor's
Data reference range, defined as the top 95% for typical
children who are not undergoing chelation therapy) were
allowed to continue on to Phase 2. Note that this level was
somewhat arbitrary, and was chosen so that only children
with significant toxic metal excretion would enter phase
two.
Phase Two
1) The blood chemistry, CBC, and RBC glutathione were
re-measured at the beginning of phase 2. If liver and renal
function were normal, if CBC's were not low, and if there
was significant excretion of metals in Phase I, then the
children were selected to continue into phase two
2) Autism Diagnostic Observation Schedule (ADOS)
examinations were administered (approximately 1 hour
assessment) by an ADOS-certified evaluator to further
characterize the participants. Each child was always exam-
ined by the same evaluator at the beginning and end. Of
the 41 participants that were evaluated and finished the
study, 81% met the criteria for Autism, 12% more met the
criteria for ASD, and 7% did not meet the criteria for ASD,
according to the sum of the Communication + Social
Scores. All children continued on in the study, since they
all had a previous clinical diagnosis of ASD.
3) Parents filled out two questionnaires on severity of
autism, the Pervasive Developmental Disorders - Behavior
Inventory (PDD-BI) and Severity of Autism Scale (SAS).
4) Children received the DMSA or placebo, and took them
for up to 3 rounds. Each round consisted of 3 days of
DMSA/placebo (as in Phase 1), followed by 11 days of no
DMSA/placebo. The children who had originally received
glutathione lotion were given DMSA, and those who had
received the placebo "glutathione" lotion received the pla-
cebo "DMSA". The families continued to be blinded in the
second phase of the study. This design resulted in one
group of children who had topical glutathione and oral
DMSA challenge followed by continued administration of
DMSA and a second group of participants who underwent
a single round of DMSA challenge without topical glutath-
ione and who subsequently did not receive any further
chelation.
5) Urine was collected after the 9th dose of DMSA (or pla-
cebo) at the end of the 2nd round in Phase 2. This was
shipped to Doctor's Data for testing.
6) After the 3rd round of DMSA (or placebo) in Phase 2,
blood chemistry and CBC were measured again. If chil-
dren had normal kidney/liver function and normal CBC,
and if they continued to have elevated excretion of toxic
metals in their urine based on their 2nd round of testing,
they were given another 3 rounds of DMSA/placebo.
7) After the 6th round of DMSA in Phase 2, a final blood
chemistry and CBC were measured.
8) When the participants finished Phase 2 (after either 3
or 6 rounds), an ADOS evaluation was conducted by the
same evaluator who conducted the first evaluation. The
parents again filled out the ATEC, SAS, and PDD-BI, as
well as the Parental Global Impressions questionnaire.
The professional working with the child was asked again
to fill out the ATEC form for the child.
Dosage of DMSA
The dosage of oral DMSA was 10 mg/kg per dose, in 3
doses per day. This is the dosage recommended in the
Physician's Desk Reference (PDR), and the dosage we
used in our previous 9-dose study [18].
Placebo
The placebo was methyl cellulose, an inert material com-
monly used as a filler. It was packed in identical pills and
bottles as the DMSA. Since DMSA has a strong smell, each
bottle included a small slotted container that contained
DMSA, so that the medication smell was present in the
container.
Dosage of Glutathione
The daily topical dosage of glutathione was approximately
180 mg of reduced l-glutathione in a lotion of isopropyl
myristate, mineral oil, caprylic/capric trigliceride, and
vitamin E acetate. The placebo was identical in packaging
and formulation except it did not contain glutathione.
Table 1: Characteristics of Participants
Total Phase 2 - treatment Phase 2 - placebo
Total Participants 77 26 15
Male 69 24 14
Female 82 1
Age (years) 6.3 6.7 6.5
Diagnosis 95% autism, 3% PDD/NOS, 3% Asperger's 96% Autism, 4% Aspergers 100% AutismBMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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Chemistry Panel and Complete Blood Count (CBC)
Measured by Quest Laboratories.
Urine Testing
Toxic and essential minerals were measured by Doctors'
Data, using Inductively-Coupled Plasma -Mass Spectrom-
etry, and creatinine was measured using the Jaffe method.
The laboratory was blinded to treatment and placebo
groups.
Red Blood Cell (RBC) Glutathione
Most glutathione in whole blood is found in the erythro-
cyte. RBC glutathione was measured by Immunosciences
Lab using a kit provided by Oxis Research (Foster City,
CA). The method is based on the formation of a chromo-
phoric thione. The absorbance measured at 405 nm is
directly proportional to the GSH concentration.
Statistical Analysis
Several types of statistical analyses were used, depending
on the research question being addressed. Pearson Corre-
lation coefficients were obtained to determine the
strengths of linear relationships among the variables
involved in the analyses. In comparing pre/post levels
within a group (such as change in urinary metal excretion
or changes in a participant's autism severity), 2-sided
paired t-tests were used, and for each individual hypothe-
sis a p value of 0.05 or lower was assumed significant for
individual analyses. However, when multiple compari-
sons were considered, then a Bonferroni correction was
used.
Since this study is largely exploratory, we examined the
relationships among several of the measured quantities,
for example the relation between changes in the various
autism severity measurement and changes in excretion
levels of toxic metals after the first dose of DMSA in phase
1, or the relationship between initial glutathione levels
and initial toxic metals excretion levels in subjects prior to
the administration of the first dose of DMSA in Phase 1.
For the selected dependent and independent variables,
step-wise linear regression analyses were conducted; at
each step, the variable with the highest p-value was elimi-
nated, and this process was continued until the adjusted
R2 value began declining. Thus, the goal was to determine
the best fit to the database for the selected model, taking
into account the correlation among the independent vari-
ables. Since the database had a few missing values (due to
missing lab or behavioral data), the regression analyses
were conducted in two slightly different ways which gen-
erally yielded very similar results: 1) eliminate all partici-
pants with missing data for any of the variables in the
model at the beginning of the analysis, and 2) eliminate
participants on an as-needed basis (i.e., only where there
is missing data for any variable in the current step in the
analysis). Since these two methods generally yielded very
similar results, we usually only report the results for
method 1). The only exception was for the change in the
ADOS, in which case we report the results of both meth-
ods.
Participation
Phase 1 Participation
We began with 82 participants, enrolled on a rolling basis.
77 completed the initial blood draw, and 65 completed
Phase 1. Of the initial 82:
One did not qualify for the study due to elevated liver
enzymes. Four stopped after the physical examination.
Eleven stopped after the initial blood draw (in two cases
this was due to difficulty in collecting urine samples). One
participant took DMSA and collected a urine sample, but
did not send it to the lab due to lack of interest/time.
Participant Transition to Phase 2 and Adverse Events
Of the 65 children who completed Phase 1, 49 continued
to phase 2. Nine children were not allowed to continue to
Phase 2; in 8 cases this was due to low urinary excretion of
toxic metals, and in 1 case it was due to extremely high
lead excretion (both at baseline and after DMSA). (This
patient was referred for follow up to their primary care
physician for evaluation of acute lead exposure). Another
7 families did not continue for personal reasons unrelated
to the study.
Finally, there was one case of a mild adverse reaction
(lethargy, decreased appetite) during Phase I, and that
family decided not to continue into Phase 2.
Phase 2 Participation
49 children began Phase 2, and 41 finished (including 5
in treatment group who finished early due to low excre-
tion of urinary toxic metals after 2nd round of DMSA in
Phase 2.
￿ 1 was discontinued due to elevated liver enzymes due to
their psychiatric medication.
￿ 1 dropped due to a death in the family
￿ 2 dropped due to perceived lack of benefit - 1 was on
placebo, and 1 was on DMSA.
￿ 4 dropped due to adverse effects:
sleep problems (on DMSA)
behavior and some skills worsened (on DMSA)BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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behavior worsened, more self-stimulatory behavior -
(on placebo)
behavior worsened, some regression (on placebo)
In most cases adverse symptoms were temporary and
resolved within a week after stopping treatment. In one
case of a child on DMSA, the child had a history of gaining
and losing skills, and the parents thought that the child
did permanently lose some skills during the study. How-
ever, the ADOS scores on that child were either
unchanged (Communication, Sociability) or improved
(Play: 2 to 1, Stimulatory Behavior/Restricted Interests: 4
to 2) from the beginning to the end of the study.
5 participants completed Phase 2, Round 2, but their uri-
nary excretion of toxic metals had decreased below our
cut-off and did not qualify them to continue into the rest
of Phase 2; so, they completed the study after receiving 1
round of DMSA in Phase 1 and 2-3 rounds in Phase 2.
Results
Urinary Excretion - Toxic Metals
One participant's results were excluded from the general
analyses in this section and elsewhere because she had
extremely high levels of many toxic metals both at base-
line and after taking DMSA, including extremely high
baseline aluminum (63× average of other participants),
antimony (45× average), bismuth (40× average), cad-
mium (7× average), lead (12× average), tin (12× average)
and uranium (65× average). After DMSA, her excretion of
antimony increased to 24× her baseline (1000× the aver-
age baseline), lead increased to 2.4× her baseline, and
excretion of other metals was less affected. This partici-
pant did not continue into phase 2 so that she could pur-
sue private treatment.
For all other participants, Table 2 and Figure 2a shows the
level of urinary excretion of toxic metals (normalized per
gram creatinine) at baseline (beginning of Phase 1, before
taking any DMSA), and after the first and 9th doses of
DMSA in the Phase 1 challenge round. The metals are
listed in order of effect of DMSA on excretion. There was
a very large and extremely statistically significant increase
in excretion of lead. There were also large and significant
increases in excretion of tin and bismuth. There was a
large increase in excretion of uranium, but it was not sta-
tistically significant (only 14-15 participants had detecta-
ble excretion of uranium before or after taking DMSA).
There was a large and highly significant initial increase in
excretion of mercury, but at the 9th dose the excretion was
only slightly higher than baseline and not statistically sig-
nificant. There were significant increases in excretion of
thallium, antimony, and tungsten. There was little change
in levels of aluminum or cadmium. There was a small ini-
tial decrease in excretion of nickel, and a small decrease in
excretion of arsenic at the 9th dose only. Due to multiple
comparisons (12 metals), only p-values below 0.004
should be considered significant, and p values between
0.05 and 0.004 should be considered marginally signifi-
cant.
The effect of the glutathione lotion on excretion of toxic
metals was analyzed by comparing the groups receiving
the DMSA + glutathione lotion vs. DMSA + placebo
lotion. In general there were no statistically significant dif-
ferences in the two groups when comparing the average
excretion after dose 1 plus after dose 9 vs. baseline. How-
ever, the excretion of mercury was possibly higher (p =
0.06) for the group receiving the DMSA + glutathione
(average excretion of 1.38 vs 0.91, vs. baseline of 0.73 and
0.80, units of mcg/g creatinine, respectively).
Table 3 and Figure 2b shows the data for urinary excretion
of toxic metals for the participants who were in the treat-
ment group in Phase 2 (n = 20). The table lists both their
Phase 1 results (1st and 9th dose) and their Phase 2 results
(after round 2, 4, and 6 of DMSA in Phase 2). Table 3 lists
the metals in the same order as in Table 2 for convenience.
Note that the number of participants in this group is
smaller than in Table 2 (n = 20 vs. n = 63, respectively),
which affects which results are statistically significant. In
general, the results for phase 2 were similar to those for
phase 1. Overall, there was a very large increase in excre-
tion of lead, some increases in excretion of tin, bismuth,
mercury, and thallium, possible ncreases in excretion of
uranium, antimony, tungsten, nickel, and decreases in
excretion ofi cadmium and arsenic. The increased excre-
tion of lead persisted throughout the entire study, and
mercury excretion also generally continued with some
fluctuations.
Table 4 lists the correlations of urinary metal excretion
with one another at baseline, Table 5 lists the correlations
at 9th dose of Phase 1, and Table 6 lists the correlations at
9th dose vs. Baseline. Most of the metals have one or more
significant correlations with other metals, so that regres-
sion analysis had some difficulty in distinguishing the
effect of one metal from another. Since multiple compar-
isons were made, only p values less than 0.01 are listed.
Urinary Excretion of Essential and Other Minerals
Table 7 and Figure 3 show the average urinary excretion of
essential and other metals for Phase 1, including the val-
ues at baseline, and the percentage change after the 1st
dose of DMSA and after the 9th dose of DMSA in Phase 1.
There was a large and statistically significant excretion of
copper, potassium, and manganese. Excretion of iron
increased and was marginally statistically significant.
There was a moderate initial increase of excretion of vana-BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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Percentage change in urinary excretion of toxic metals Figure 2
Percentage change in urinary excretion of toxic metals. a: Percentage Change in Urinary Excretion of Toxic Metals 
after 1st and 9th Dose of DMSA in Phase 1. (n = 63). b: Percentage Change in Urinary Excretion of Toxic Metals after 1st and 9th 
dose of Round 1, and then 9th dose of Rounds 3, 5, and 7, for the group who received 7 rounds of DMSA. (n = 20).BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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dium, chromium, sodium, and boron, but then they were
similar to baseline by the 9th dose. The excretions of zinc
and magnesium were initially similar to baseline and then
had a moderate increase by the 9th dose. There were large
average increases in zirconium and lithium (due to a few
outliers), but the increases were not statistically signifi-
cant. The excretion of barium, sulfur, selenium, cobalt,
calcium, strontium, and phosphorus were not signifi-
cantly affected. There was a moderate decrease in the
excretion of molybdenum at the 9th dose which was mar-
ginally significant. Since multiple comparisons were
made, only p values below 0.003 should be considered
significant.
Table 7 also lists the extra loss of essential minerals, in
terms of the fraction of the Recommended Daily Allow-
ance (RDA) lost each day, based on two reasonable
assumptions: 1) averaging the loss between the 1st and 9th
dose, and 2) assuming a daily urinary excretion of 500
mcg of creatinine, which is typical of a 60-pound child.
On that basis, there was a large daily loss of chromium
(88% of the RDA) and potassium (57% of the RDA). The
amount of loss of other essential minerals was negligible
(less than 6% of the RDA).
It should be noted that all the participants were taking a
vitamin/mineral supplement for at least two months prior
Table 2: Urinary excretion of toxic metals in Phase 1, at baseline, after 1st dose, and after 9th dose, in mcg/g creatinine. 
Element Baseline 1st Dose 9th Dose 1st dose vs. baseline 9th dose vs. baseline
Pb 1.3 +/- 2.3 10. +/- 19. 9.2 +/- 7.8 713%*** 638%***
Sn 2.3 +/- 3.4 8.0 +/- 13 9.7 +/- 24 241%*** 314%*
Bi 0.18 +/- 0.45 0.47 +/- 1.4 0.41 +/- 1.0 161%+ 128%*
U 0.015 +/- .04 0.036 +/- .09 0.031 +/- .1 104% 111%
Hg 0.86 +/- .92 1.5 +/- 1.4 0.97 +/- 0.88 70%** 13%
Tl 0.15 +/- 0.12 0.25 +/- 0.18 0.21 +/- 0.19 67%*** 42%**
Sb 0.10 +/- 0.10 0.15 +/- 0.19 0.14 +/- 0.20 49%* 42%+
W 0.39 +/- 0.29 0.59 +/- 0.63 0.46 +/- 0.50 51%** 18%*
Al 16 +/- 21 18 +/- 23 19 +/- 33 11% 21%
Ni 6.7 +/- 5.1 5.5 +/- 3.6 7.6 +/- 4.3 -18%* 12%
Cd 0.38 +/- 0.24 0.40 +/- 0.24 0.33 +/- 0.23 5% -14%
As 32 +/- 20 32 +/- 18 25 +/- 18 0% -19%*
creatinine 94 +/- 52 62 +/- 39 80 +/- 43 -34%*** -15%*
+ P < 0.1
*P < 0.05
** P < 0.01
*** P < 0.001
Creatinine values have units of mg/dl. N = 63. The metals are listed in approximate order of effect of DMSA on excretion. Significant results are 
highlighted in bold font.
Table 3: Comparison of change in average urine excretion compared to baseline for participants who completed six rounds of phase 2 
(n = 20). 
Element Baseline
(mcg/g- creatinine)
Change after 1st
dose
Change after 9th
dose
Change after
round 2
Change after
round 4
Change after
round 6
Pb 0.64 935%*** 1562%*** 1001%*** 1063%*** 1005%***
Sn 3.5 118%* 269% 205% 213% 115%
Bi 0.06 312% 296% 787% 261% 11%
U 0.014 29% 79% -32% -11% 282%+
Hg 0.85 120%* 37% 98%*** 70% 59%+
Tl 0.16 54%** 44%* 13% 18% 28%
Sb 0.10 67%+ 26% 9% 23% 27%
W 0.41 36%+ -11% 14% 52% 25%
Al 8.3 125% 1% 26% 38% -12%
Ni 5.8 -2% 25% 36%+ 68%* 25%
Cd 0.35 14% -32%* -7% 0% -17%
As 31 4% -13% -39%*** -42%*** -31%+
+ P < 0.1
*P < 0.05
** P < 0.01
*** P < 0.001
Significant results are highlighted in bold font.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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to and throughout the study, to minimize effects due to
possible loss of essential minerals.
RBC Glutathione
The level of glutathione in the Red Blood Cells (RBC) was
measured at baseline and at the beginning of Phase 2 (for
those who continued on to phase 2), which was typically
1.5 months (42 days +/- 33) after taking the DMSA. The
values are given in Table 8 and Figure 4. Initially there was
a very broad distribution of levels, with some being lower
or higher than the lab's reference range for adults, defined
as +/- 2 standard deviations around the mean. (It should
be noted that children tend to have lower levels than
adults, but the laboratory did not have a pediatric refer-
ence range.) After administration of DMSA, there was lit-
tle change in the average level (a small decrease, not
statistically significant), but the standard deviation
became dramatically smaller. Figure 4c plots the average
change in glutathione vs. the initial level. The change in
glutathione level had an extremely high inverse correla-
tion (-0.96, p < 0.0001) to the initial glutathione. Specifi-
cally, the children with unusually low initial levels had a
large increase in glutathione towards the average value,
those children with unusually high initial levels had a
large decrease towards the average value, and those with
initially average values had little change. Note that the
change was very similar regardless of whether the partici-
pants were receiving the glutathione lotion or the placebo
lotion, suggesting that the effect was due to the DMSA.
RBC Glutathione and Heavy Metals
Correlation analysis found that baseline RBC glutathione
(before DMSA) had significant positive correlations with
urinary excretion of several metals (at baseline and after
9th dose of DMSA), including baseline Sb (r = 0.26), and
post-9th dose urinary excretion of Pb (r = 0.25), Al-9 (r =
0.29), and Cd (r = 0.30), suggesting that increased levels
of these metals correlated with increased RBC glutathione.
This suggests that the body responds to increased levels of
most toxic metals by increasing the production of RBC
glutathione. However, there was a negative correlation of
RBC glutathione with excretion of mercury at the 9th dose
(r = -0.27), which suggests that mercury has an adverse
effect on RBC glutathione, presumably by both causing it
to be excreted from the body after the glutathione binds
to mercury, and perhaps more importantly by inhibiting
production of glutathione. It is very interesting that mer-
cury, and only mercury, has a significant negative correla-
tion with RBC glutathione, and again suggests the special
importance and toxicity of mercury.
A stepwise linear regression analysis for predicting initial
glutathione was conducted based on the urinary excretion
of toxic metals at baseline and after the 9th dose of DMSA.
The results are shown in Table 9. It was found that the ini-
tial glutathione could be partially predicted (adjusted R2 =
0.25, p = 0.003) based primarily on excretion of cad-
mium, lead, tin, thallium, and arsenic.
A similar analysis was conducted for the change in glu-
tathione between baseline and after the first round of
DMSA, and it was found that the change in glutathione
could be partially predicted (adjusted R2  = 0.29, p =
Table 4: Significant Correlations of Baseline Urinary Metal 
Excretion with Baseline Urinary Metal Excretion (only 
correlations >0.31 in magnitude are listed, corresponding to p = 
0.01 on an individual comparison basis)
Metal Correlations
Pb Tl (0.37), As (0.44), Al (0.41)
Sn Tl (0.36), Sb (0.34)
Hg Sb(0.42)
Tl Sn (0.36)
Sb Sn (0.34), Hg (0.42)
W none
Al Pb(0.41)
Cd none
As Pb(0.44)
Table 5: Significant Correlations of Phase 1, 9th dose Urinary 
Metal Excretion with Phase 1, 9th dose Urinary Metal Excretion 
(only correlations >0.31 in magnitude are listed, corresponding 
to p = 0.01 on an individual comparison basis)
Metal Correlations
Pb Tl(0.47), Sb(0.35), Al (0.56)
Sn none
Hg none
Tl Pb(0.47)
Sb Pb(0.35), Cd(0.67), Al (0.63)
W None
Al Pb (0.56), Sb (0.63), Cd (0.67)
Cd Sb (0.67), Al (0.67)
As Pb (0.56), Sb (0.63), Cd (0.67)
Table 6: Significant Correlations of Phase 1, 9th dose Urinary 
Metal Excretion with Baseline Urinary Metal Excretion (only 
correlations >0.31 in magnitude are listed, corresponding to p = 
0.01 on an individual comparison basis)
Metal at 9th dose Correlations with baseline excretion
Pb Pb(0.40), Tl(0.51),
Sn W(0.38)
Hg none
Tl Tl(0.54), W(0.31)
Sb Pb(0.81), Tl(0.34), As(0.40), Al(0.38)
W None
Al Pb(0.59), As(0.33), Al(0.35)
Cd Pb(0.62), As(0.42), Cd(0.38), Al (0.40)
As Pb(0.59), As(0.33), Al(0.35)BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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0.002) based primarily on excretion of cadmium after the
9th dose in phase 1 (see Table 9). This is consistent with
the correlation analysis above.
Complete Blood Count
Table 10 shows the results of the initial complete blood
count for 77 participants, prior to any treatment. The only
somewhat unusual feature at the initial blood draw was
that 18% had elevated platelets (reference range of 130-
450 k/mm3), a marker of inflammation. The % Lym-
phocytes tended to be slightly above or below the refer-
ence range, but the absolute lymphocytes were almost all
within the reference range.
Table 11 shows the changes in Complete Blood Count
(CBC), measured before and 1.5 months (42 +/- 33 days)
after the first round of DMSA. The only significant change
was a 6% decrease in platelet count (p = 0.02). The
decrease in platelet count was primarily in the group with
an initial level above the reference range (decrease of 70
k/mm3), whereas the group initially in the reference range
had much less change (decrease of 24 k/mm3), and the
one child with an initially low level had an increase of 26
k/mm3 The correlation of the. initial platelet level and the
change was -0.32, p = 0.05. Figure 5a shows the initial dis-
tribution of platelet count, Figure 5b shows the value 1-2
months after the first round of DMSA, and Figure 5c
shows the values at the end of phase 2 for both groups.
Overall, the many children with initially high levels had a
decrease towards the normal range, and the one child with
an initially low value had an increase towards the normal
range. It is interesting to note that one child had an
extremely high initial value of 1996 k/mm3, and it
decreased by the end of the study to 1195 k/mm3.
White blood cell count was investigated carefully, due to
concerns about the possible effect of DMSA on it. For the
7-round group there was a 7% decrease in white blood cell
count (not significant), with 1 child initially having a high
level, and at the end 1 child having a high level and one
child ending with a level slightly below the reference
range (3.9 k/mm3, compared to a reference range of 4.0-
12.0 k/mm3). The child who ended with a slightly low
level had started with a level of 4.9 k/mm3; at the begin-
ning of phase 2 it was 3.6, then in the middle of the study
it was 5.2 k/mm3, so the total white blood cell count fluc-
tuated near the bottom of the reference range during the
study, but at no point was the participant either neutro-
penic or lymphocytopenic. For the 1-round group, there
was an 8% decrease (not significant) in white blood cell
count with one child initially having an elevated level,
and all being normal at the end of the study.
Loss of Essential Minerals, averaged over the 3 days of DMSA therapy in Phase 1, in units of the % RDA Figure 3
Loss of Essential Minerals, averaged over the 3 days of DMSA therapy in Phase 1, in units of the % RDA. The 
only major losses are chromium and potassium.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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A stepwise linear regression analysis of initial platelet
count did not reveal any significant relationship with uri-
nary excretion of toxic metals (at baseline and after 9th
dose) and initial glutathione. However, a similar analysis
for the change in platelet count from beginning of phase
1 to the beginning of phase 2 was performed, with excre-
tion of toxic metals after the 9th dose of DMSA and change
in glutathione as the dependent variables. It was found
that the change in platelet count could be partially
explained (adjusted R2 = 0.41, p = 0.02), with the major
factors being Tl (p = 0.002), As (p = 0.01), Cd (p = 0.03),
and change in glutathione (p = 0.04). Table 12
Chemistry Panel
Table 10 shows the results of the initial blood chemistry
panel for 77 participants in Phase 1. The major unusual
feature was the abnormally high Blood Urea Nitrogen
(BUN)/Creatinine ratio, an indicator of kidney function.
Initially, 43% of the children had a value above the labo-
ratory's reference range, and none had a level below the
reference range. This was largely due to low serum creati-
nine (22% of the children had levels below the reference
range, and none had levels above it). The BUN values
were almost all within the reference range, but tended to
be in the higher end of it.
Table 11 also shows the changes in blood chemistry,
measured before and 1.5 months (42 +/- 33 days) after the
first round of DMSA. There were no statistically significant
changes in blood chemistry. However, it is interesting to
note that initially 17/42 participants had elevated Blood
Urea Nitrogen (BUN)/Creatinine ratios, and after the
DMSA it decreased 6% (not significant), so that only 14/
42 had elevated levels, and 1/42 had low levels. The rea-
son for the initial elevated ratio is largely due to low creat-
inine (in 8/42 children), whereas none had high initial
BUN values. Low creatinine was defined as less than 0.4
(younger) or 0.5 (older) mg/dl. Overall, this suggests
there was no worsening of kidney function.
Stepwise linear regression analysis found that the varia-
tions in initial BUN/Creatinine ratio could be partially
predicted by urinary metal excretion at baseline and after
the 9th dose of Phase 1, with an adjusted R2 = 0.35, p =
0.0001, with the most significant factors being baseline Sn
(p = 0.003), baseline W (p = 0.02), and 9th dose Sb (p =
0.05).
A similar analysis found that the changes in BUN/Creati-
nine from beginning of phase 1 to beginning of phase 2
could be partially predicted (adjusted R2 = 0.51, p = 0.05,
Table 7: Comparison of average urine excretion of essential and other minerals compared to baseline. 
Baseline st dev Change after 1st dose Change after 9th dose RDA for 4-8 yr (mg) % of RDA lost #
Cu 0.022 0.008 74%*** 129%*** 0.44 3%
K 2187 1491 110%*** 48%** 1500 57%
Fe 0.016 0.055 93%+ 64% 10 0.1%
Mn 0.0023 0.0016 77%*** 37%* 1.5 <0.1%
Zi 0.00034 0.00069 90% 13% n/a
Li 0.10 0.10 51% 50% n/a
V 0.025 0.013 49%*** 10%
Cr 0.091 0.044 47%*** 11% 0.015 88%
Zn 0.81 0.49 8% 30%*** 5 2%
Na 3901 2018 35%*** 3% n/a
B 2.5 2.0 25%* 11% n/a
Ba 0.0050 0.0052 12% 22% n/a
S 1140 694 3% 9% n/a
Mg 168 64 -5% 17%* 130 4%
Se 0.20 0.16 3% 0% 30 6%
Co 0.0014 0.0013 -4% 4% n/a
Ca 137 115 -6% 3% 800 no extra loss
St 0.25 0.15 -5% 0% n/a
P 1160 627 -5% -4% 500 No extraloss
Mo 0.13 0.13 -5% -33%* 0.022 No extra loss
+ P < 0.1
*P < 0.05
** P < 0.01
*** P < 0.001
# Averaged over 3 days, assuming production of creatinine is 500 mcg/day, which is typical for a 60-pound child
N = 63. Units are mg/g-creatinine (note difference from table 2 and 3, which are mcg/g-creatinine). Arranged in approximate order of increase in 
urinary excretion. The extra loss of minerals due to increased urinary excretion is also listed in terms of the RDA. Results for potassium (K) and 
chromium (Cr) are highlighted due to the large % of RDA.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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RBC glucathione distributions Figure 4
RBC glucathione distributions. a: Initial RBC Glutathione Distribution (pre-treatment). Many autistic children 
have levels below and above the laboratory's reference range of 427-714 micromolar. Each histogram corresponds to the fre-
quency between that value and 50 below it; ie, the histogram labelled "50" is the frequency of values from 0 to 50. b: RBC 
Glutathione Distribution 1-2 months after first round (3 days) of DMSA. The distribution has tightened dramatically, 
so that most children are within the laboratory's reference range for typical adults. c: Change in RBC glutathione 1-2 
months after first round of DMSA. Children with initially low levels had a large increase in glutathione, and children with 
high levels had a large decrease, so that most levels of glutathione normalized. The black dots are the participants who received 
DMSA and glutathione lotion and the red dots are the participants who received DMSA and the placebo lotion. The trendlines 
for the two groups lie directly on top of one another, suggesting that the effect of the glutathione lotion is negligible compared 
to the effect of the DMSA.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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with the most significant factors being 9th dose Hg (p =
0.01), change in glutathione (p = 0.02), 9th dose Tl (p =
0.04), and 9th dose Pb (p = 0.05).
At the end of phase 2, the 7-round treatment group did
not have any significant changes in blood chemistry.
There was a possible trend of a small decrease in eosi-
nophils (-18%, p = 0.08), with initially 3/21 high, and
only 2/21 high at the end of the study. There was also a
possible trend of an increase in triglycerides (+47%, p =
0.06) - initially all were normal, and at the end of the
study 2/21 were elevated. In contrast, in the 1-round treat-
ment group, there was a 15% decrease (not significant) in
triglycerides levels. It should be noted that these were not
fasting measurements, so the fluctuations could be diet-
related.
It is interesting to note that there was a 12% increase (not
significant) in alkaline phosphatase, with initially 0/42
having abnormal levels, and 5/42 having elevated levels at
the end of the study. Elevated alkaline phosphatase is
associated with growth spurts, and it is expected that chil-
dren in the study age range will normally have growth
spurts.
Heavy Metal Exposure Questionnaire
Table 13 lists the medical history data that relates to toxic
metal exposure, as reported by the parents. Some of these
factors were analyzed to determine if they correlated with
severity of autism. Maternal fish consumption (a primary
source of mercury) and total oral antibiotic use (which
inhibits excretion of mercury) over the first 3 years of life
did not significantly correlate with any of the autism
severity scales at baseline. The number of maternal mer-
cury amalgam fillings did not correlate with the SAS,
PDD-BI autism scale or the ADOS total, but there was a
negative correlation (-0.33) of the ATEC total with mater-
nal mercury dental fillings - this is unexpected, as it sug-
gests that a higher number of mercury fillings was
associated with less severe autism.
Table 14 shows the strong correlation of "eating/licking
paint" and pica with the autism severity scores and with
metal excretion. It should be noted that the correlation
scores are generally quite similar for both the autism
severity scales and for metal excretion.
Discussion
Urinary Excretion - Toxic Metals
DMSA greatly increased the excretion of lead, which is not
surprising since it is FDA-approved for treating lead poi-
soning. There were also large increases in tin and bismuth
(which are less toxic), some increases in mercury, thal-
lium, antimony, and tungsten, and possible increases in
uranium and (in later rounds) nickel. There was generally
little effect on cadmium, arsenic, or aluminum.
Only 20% of the children had their therapy stopped after
round 3 of phase 2, due to a decrease in urinary excretion
below our chosen criteria. In 80% of the cases the level of
excretion of lead remained high even at the end of round
6 in phase 2, suggesting that more rounds were needed.
When this study was designed, it was unknown how long
to treat for, and this data suggests that longer treatment is
needed by most children to further reduce levels of lead
and other toxic metals. Other medications, such as DMPS,
would be more effective in removing mercury. It appears
that other medications would be needed to treat cad-
mium, arsenic, or aluminum toxicity, if present.
It is interesting to compare the results of this study with
the study by Bradstreet et al. 2003 as in phase 1 we repli-
cated their dosing (9 doses over 3 days, 10 mg/kg-dose).
In that study, they did not measure the baseline urinary
excretion, but they did measure urinary excretion after 9
rounds of DMSA, at the same dosage we used. They
reported a higher excretion of lead after 9 rounds of DMSA
(18.2 +/- 43.3 vs. 9.2 +/- 7.8 mcg/g-creatinine). They
found much higher excretion of mercury (6.4 +/- 13 vs.
0.97 +/- 0.88 mcg/g-creatinine) and slightly higher excre-
tion of cadmium (0.48 +/- 0.42 vs. 0.33 +/- 0.23). Samples
were collected in a similar fashion in both studies, and the
measurements were done by the same laboratory, so a col-
lection or measurement error is unlikely. Rather, it
appears that the population in the Bradstreet et al study
had a higher body burden of lead, mercury, and cad-
mium, perhaps because they were slightly older (6.2 yr,
range 3 to 15 years) or more likely because they were from
Table 8: Glutathione levels before and 1-2 months after 1st round of DMSA in Phase 1 (just prior to Phase 2). 
Average Glutathione Level
Range
Baseline - all (n = 72) 501 +/- 246 31-1033
Baseline - those with a 2nd measurement in phase 2 (n = 38) 523 +/- 280 31-1033
1-2 months after 1st round DMSA (n = 38) 478 +/- 83 355-695
Immunosciences Reference Range for Adults 427-714
There is a dramatic change in the standard deviation.3BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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Table 9: Regression analysis of initial glutathione and change in glutathione (from before and after phase 1). 
Adjusted R2 P-Value Equation Most Significant variables
Glutathione (n = 59) 0.25 0.003 378.7-48.8 PbB + 3.67AsB -219 CdB +2.49 Sn9 
+369 TlB -69.9 Hg9 -4.32 As9 +598 Cd9
Cd9**, PbB*, Sn9*, Tl9*, As9*
Change in glutathione (n = 37) 0.29 0.002 104-2.26Sn9+87.8Hg9-669Cd9 Cd**
The analysis involved metals at Baseline (B) and after the 9th dose (9).
Table 10: Complete Blood Count and Chemistry Panel at baseline (N = 77). 
Average Value Stnd Dev % Below RR % Above RR
WBC (k/mm3) 8.04 2.90 1% 9%
RBC (m/mm3) 4.56 0.29 4% 1%
HEMOGLOBIN(g/dL) 13.0 0.76 1% 3%
Hematocrit (%) 37.9 2.27 1% 1%
MCV (fL) 83.3 3.21 0% 4%
MCH (pg) 28.6 1.16 3% 3%
MCHC (g/dL) 34.4 0.73 0% 0%
RDW (%) 13.4 0.70 0% 4%
Platelet count (k/mm3) 388 208 1% 18%
MPV (fL) 8.53 1.02 8% 3%
Seg Neutrophils 44.5 12.6 8% 9%
Lymphocytes (%) 44.7 11.6 12% 13%
Monocytes (%) 7.15 1.91 0% 3%
Eosinophils (%) 3.42 2.55 0% 8%
Basophils (%) 0.41 0.52 0% 0%
Abs Neutrophil (K/uL) 3.80 2.35 0% 8%
Abs lympocyte (k/uL) 3.29 0.87 1% 0%
Abs Monocyte (k/uL) 0.55 0.21 0% 1%
Abs Eosinophil (k/uL) 0.24 0.17 0% 0%
Abs Basophil (k/uL) 0.02 0.04 0% 0%
Glucose (mg/dL) 87.9 14.9 3% 16%
Urea Nitrogen (mg/dL) 13.7 4.18 1% 0%
Creatinine 0.50 0.09 22% 0%
Bun/Creat Ratio 28.0 8.45 0% 43%
Uric Acid (mg/dL) 3.93 0.82 1% 4%
Sodium (mmol/L) 140 2.33 1% 1%
Potassium (mmol/L) 4.39 0.45 0% 4%
Chloride (mmol/L) 104 2.20 0% 0%
CO2 (mmol/L) 22.3 2.28 9% 0%
Anion gap 13.6 2.52 0% 3%
Osmolality (mOs/kg) 284 5.15 1% 1%
Protein (g/dL) 7.23 0.48 0% 3%
Albumin (g/dL) 4.57 0.21 0% 0%
Globulin (g/dL) 2.70 0.34 0% 1%
Alb/Glob Rat 1.73 0.23 0% 6%
Cholesterol (mg/dL) 150 25.2 0% 14%
Triglyceride (mg/dL) 100 62.2 0% 13%
Calcium (mg/dL) 10.0 0.37 0% 3%
Phosphorus (mg/dL) 5.04 0.61 0% 9%
Alkaline Phosphate (IU/L) 237 64.9 0% 8%
GGT (IU/L) 10.3 3.13 0% 1%
ALT (IU/L) 20.1 8.03 0% 4%
AST (IU/L) 35.2 8.45 0% 6%
Lactic Dehydrogenase (IU/L) 253 56.2 1% 6%
Bilirubin (mg/dL) 0.34 0.25 8% 0%
The major abnormalities are elevated platelet counts, low creatinine, and elevated BUN/creatinine ratio.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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Table 11: Complete Blood Count and Chemistry Panel at baseline and after 1 round of DMSA (N = 41). 
Baseline
Average Value
Stnd Dev % Below RR % Above RR % change After 1st
DMSA
% Below RR % Above RR
WBC (k/mm3) 7.76 2.50 0% 12% -3% 5% 2%
RBC (m/mm3) 4.60 0.27 0% 2% 0% 0% 0%
HEMOGLOBIN
(g/dL)
1 3 . 2 0 . 6 90 %2 % 1 %0 %5 %
Hematocrit (%) 3 8 . 5 2 . 0 50 %2 % 0 %2 %0 %
MCV (fL) 8 3 . 8 2 . 9 40 %2 % 0 %0 %2 %
MCH (pg) 2 8 . 7 0 . 9 80 %2 % 0 %0 %2 %
MCHC (g/dL) 3 4 . 3 0 . 7 20 %0 % 0 %0 %0 %
RDW (%) Platelet 
count
1 3 . 4 0 . 5 50 %0 % 0 %0 %7 %
(k/mm3) 424 274 2% 29% -7% 0% 12%
MPV (fL) 8.59 1.14 10% 5% 1% 10% 2%
Seg Neutrophils 42.6 11.9 15% 2% 3% 20% 7%
Lymphocytes (%) 46.2 11.1 5% 17% -4% 7% 22%
Monocytes (%) 7.27 2.01 0% 2% 5% 2% 7%
Eosinophils (%) 3.78 2.91 0% 10% -1% 0% 10%
Basophils (%) Abs 
Neutrophil
0.39 0.54 0% 0% 25% 0% 0%
(K/uL) Abs lympocyte 3.34 1.53 0% 2% 2% 5% 5%
(k/uL) Abs Monocyte 3.28 0.86 0% 0% 0% 2% 0%
(k/uL) Abs Eosinophil 0.53 0.17 0% 0% 9% 0% 0%
(k/uL) 0.24 0.17 0% 0% 28% 0% 5%
Abs Basophil (k/uL) 0.01 0.03 0% 0% 140% 0% 0%
Glucose (mg/dL) Urea 
Nitrogen
85.3 12.5 5% 15% -4% 5% 7%
(mg/dL) 13.9 4.18 2% 0% -8% 0% 0%
Creatinine 0.50 0.08 20% 0% -5% 22% 0%
Bun/Creat Ratio 28.4 9.40 0% 39% -8% 2% 32%
Uric Acid (mg/dL) 3.73 0.80 2% 2% 13% 7% 0%
Sodium (mmol/L) 139 2.11 0% 0% -2% 2% 2%
Potassium 
(mmol/L)
4.41 0.46 0% 5% -2% 0% 10%
Chloride (mmol/L) 103 1.71 0% 0% -2% 0% 0%
CO2 (mmol/L) 22.8 1.96 5% 0% -5% 20% 0%
Anion gap Osmolality 1 3 . 3 2 . 4 20 %2 % 2 %0 %5 %
(mOs/kg) 284 4.83 0% 0% 12% 2% 2%
Protein (g/dL) 7.17 0.53 0% 0% 5% 0% 0%
Albumin (g/dL) 4.60 0.21 0% 0% 5% 0% 0%
Globulin (g/dL) 2.65 0.31 0% 2% 6% 0% 0%
Alb/Glob Rat 1.77 0.23 0% 12% 4% 0% 5%
Cholesterol 
(mg/dL)
147 30.1 0% 15% 19% 0% 29%
Triglyceride 
(mg/dL)
87.8 50.0 0% 7% 30% 0% 12%
Calcium (mg/dL) 10.1 0.37 0% 2% -4% 0% 10%
Phosphorus 
(mg/dL)
5.09 0.67 0% 10% 4% 0% 12%
Alkaline Phosphate 
(IU/L)
228 64.1 0% 2% 7% 0% 20%
GGT (IU/L) 10.2 2.99 0% 0% 12% 0% 0%
ALT (IU/L) 2 0 . 2 7 . 2 90 %2 % 7 %0 %5 %
AST (IU/L) 3 4 . 4 5 . 5 40 %0 % 3 %0 %0 %
Lactic Dehydrogenase 
(IU/L)
243 43.2 2% 0% 14% 2% 15%
Bilirubin (mg/dL) 0.33 0.31 10% 0% -12% 5% 2%
Data on platelets, creatinine, and BUN/creatinine is highlighted.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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a different area of the country (across the US vs. Arizona).
Unlike most of the rest of the US, Arizona has had unusu-
ally rapid population growth over the last several decades,
from 2.7 million in the 1970 census to an estimated 6.1
million in 2006. Thus, Arizona had much less use of lead
paint and leaded gasoline than other parts of the country,
and that may account for the difference in lead levels
between this study and the Bradstreet study. The differ-
ence in mercury levels between this study and Bradstreet's
study may have similar origins due to geographical differ-
ences in diet (seafood) and environmental exposure.
Therefore, it is important that geographical effects be con-
sidered when comparing toxic metal exposure from differ-
ent studies.
Urinary Excretion of Essential Minerals
Based on our measurements, DMSA does have a signifi-
cant effect on urinary excretion of several essential miner-
als. However, in most cases the amount of loss is only a
small fraction (less than 6%) of the RDA, and hence is of
minor concern. The two exceptions were potassium and
chromium, which had an average extra daily loss of 57%
and 88% of the RDA, during the 3 days of DMSA. How-
ever, since there were at least 11 days between each round
of DMSA, the effective loss over 2 weeks is much less. The
blood measurements of potassium revealed no change
over the course of the study, so the children's bodies
appeared to be able to compensate for minor loss of
potassium. Since the children were on a multi-vitamin/
mineral supplement of their choice (most of which
included chromium), the loss of chromium was probably
not a problem. In general, our data suggests that people
using DMSA should take a chromium supplement, and
consume extra fruits and vegetables (for potassium, which
is not allowed in significant levels in over-the-counter
multi-vitamin/mineral supplements).
Since the DMSA was taken orally, and since only about
20% is absorbed orally, it is possible that some of the 80%
remaining in the digestive tract bound to essential miner-
als in food, causing a decreased absorption of essential
minerals. A future study could check red blood cell levels
of essential minerals, to check for long-term effects, espe-
cially on chromium.
Glutathione
DMSA treatment had a dramatic effect on normalizing
abnormal levels of RBC glutathione. At the start of the
study, some children had unusually high levels, and the
correlation analysis suggests this was partially due to
increased production in response to higher levels of toxic
metals. Some children had unusually low levels, and cor-
relation analysis suggests this was partially due to the pres-
ence of mercury, which is known to strongly inhibit the
production of glutathione. Surprisingly, a single round of
DMSA resulted in a dramatic normalization of the abnor-
mal levels, and the effect lasted at least 1.5 months. The
effect was the same for the group receiving the glutathione
or placebo lotion, so the effect appeared to be due to the
DMSA, not the glutathione lotion. It is possible that the
DMSA's effect was partially due to its antioxidant capabil-
ity, but it seems unlikely that that effect would be long-
lasting. Instead, it seems likely that the DMSA's effect was
due to the reduction of toxic metals in the RBC, allowing
glutathione to return to a normal level. Since only 1 round
was needed to normalize the RBC glutathione, and since
the effect lasted at least 1.5 months, additional DMSA
probably would have little additional benefit. Since glu-
tathione serves many important functions in the body,
improvements in glutathione might result in improve-
ments in overall functioning, which suggests that children
receiving 1 or 7 rounds of DMSA would have similar
improvements in behavior. Table 15
Complete Blood Count
It was surprising that, at the start of the study, many of the
children had elevated platelet levels. Platelet counts are an
acute-phase reactant and an elevation is considered an
indication of inflammation somewhere in the body. The
platelet count did not significantly correlate with gut
problems, so the inflammation does not appear to be pri-
marily gut-related. It was more surprising that 1 round of
DMSA resulted in a normalization of the platelet counts
in about half of the cases, and the effects seemed to last for
at least several months.
This suggests that some of the inflammation in children
with autism is due to toxic metals which are removable by
DMSA.
There was one case of 1 child whose White Blood Cell
(WBC) count started near the bottom of the reference
range, and it fluctuated above and below that value during
the study, finally ending with a level slightly below the ref-
erence range, but without neutropenia or lymphocytope-
nia. So, although more investigation of effect of DMSA on
WBC is needed, here does not appear to be a major detri-
mental effect of t DMSA on WBC.
Chemistry Panel
There have been some reports that DMSA can slightly
increase liver enzymes in 6-10% of people when used to
treat children with lead poisoning (PDR 2008), which
typically involves 21 continuous days of DMSA therapy at
daily doses similar to that used in our study. However, we
found that the DMSA had no significant effects on liver
transaminases (AST and ALT), perhaps because we treated
for only 3 days at a time, with 11 days in-between.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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Platelet count Figure 5
Platelet count. a: Platelet Count before DMSA. Note many children have values above the reference range (130-450 k/
mm3). One child had a very high value (1996 k/mm3) which is not shown on this chart. b: Platelet Count 1-2 months after 
first round of DMSA. The primary effect of DMSA is to decrease the elevated platelets, with little effect on those in the nor-
mal or low range. One child still had a very high value (1917 k/mm3) which is not shown on this chart. c: Platelet Count at 
End of Study. Both the 7-round and 1-round groups are plotted together, as the results were similar, although there was 
slightly more decrease for the 7-round than the 1-round group. The primary effect of DMSA is to normalize elevated or (in 
one case) low platelets. One child still has a high value of 1195 k/mm3 which is not shown, but it has decreased substantially 
from its initial value of 1996 k/mm3).BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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The only possible concern about the effect of the DMSA
was a possible increase in triglyceride levels in the 7-round
group. Triglyceride levels are best measured with a fasting
blood draw, but we did not require fasting to simplify the
ease of participation in the protocol. So, it is unclear if this
result is a random artifact associated with non-fasting
blood draws, or a real effect - future studies should check
for this with a fasting blood draw.
We also found that many children had initially elevated
BUN/creatinine ratio, which was most often due to low
creatinine. The low creatinine is probably an indication of
low muscle mass in the children. The variations in ele-
vated BUN/creatinine could be partially explained with a
regression analysis based on urinary excretion of heavy
metals. This suggests that the elevations were partially due
to the presence of heavy metals, especially tin, tungsten,
and antimony. There was a small improvement in BUN/
creatinine ratio by the end of the study, but the improve-
ment was not statistically significant. There was no signif-
icant worsening of renal function of any study participant.
Overall, it appeared that the DMSA was well-tolerated.
Adverse Effects
Most participants in the study reported overall improve-
ments in their children. However, during Phase 1 there
was one report of a mild adverse reaction (lethargy,
decreased appetite), and that family chose not to continue
to Phase 2. Also, duringPhase 2, 4 children dropped out
due to adverse effects, with 2 of those children being on
DMSA, and 2 being on placebo. There were also two chil-
dren on DMSA who ended the study early because of low
urinary excretion of metals, and they had some worsening
Table 12: Stepwise linear regression analysis of change in platelet count (from baseline to beginning of phase 2, 1-2 months after 
DMSA therapy), based on excretion of metals after the 9th dose in phase one, and the change in glutathione. 
Adjusted R2 P- value Equation Most Significant 
Variables
Change in platelet count 
(both groups, n = 32)
0.41 0.02 7rnd group (3.71-331Tl9 +256Sb9+2.89As9-256Cd9-
0.118Dglut) 1rnd group 
(-81.6 +28.3Tl9- 
174Sb9+0.194As9+259Cd9+0.193Dglut)
7rnd - (Tl9***, As9**, Cd9*, 
Dglut*), 1rnd- (Dglut*)
Change in platelet count 
(7-rnd group only, n = 20)
0.41 0.02 3.71 -331 Tl9 +256Sb9 +2.89 As9 -256 Cd9 -0.118 
DGlut
Tl9**, As9**, Cd*, DGlut*
Thallium (Tl), Arsenic (As), Cadmium (Cd), and change in glutathione (Dglut) are the best predictors of change in platelet count, for the case of 
analyzing both groups and for the case of the 7-round group only.
Table 13: Medical History, as reported by parents (n = 73)
Maternal Fish Consumption (servings/month) 2.85 +/- 2.9
Mercury Amalgams present during pregnancy 3.12 +/- 3.5
Mercury amalgams placed during pregnancy 3%
Mercury amalgams removed during pregnancy 2%
Placed during Nursing 2%
Removed during Nursing 2%
Antibiotic usage during pregnancy (rounds) 0.67 +/- 1.5
Antibiotic usage during nursing (rounds) 0.39 +/- 0.83
Child usage of oral antibiotics
0-6 months 0.76 +/- 1.2
7-12 months 1.63 +/- 2.9
12-24 months 2.04 +/- 3.0
24-36 months 1.82 +/- 2.0
Total 0-36 months 5.4 +/- 6.1
Ear Infections 0-36 months 3.5 +/- 4.3
Blood Type 33% A+, 4% A-, 11% B+, 2%B- 4%AB+, 22%O+, 22%O-
Rhogam use 18%
Reactions to vaccines 38% none, 44% mild, 10% moderate, 7% severe
Eating/Licking Paint 7% mild, 4% moderate, 5% severe
Pica 16% mild, 8% moderate, 16% severe
Pregnancy Complications 31% mild, 9% moderate, 9% severe
Birth Complications 23% mild, 11% moderate, 11% severe
Childhood Illness 10% mild, 4% moderate, 6% severe
Regression 28% no regression, 30% possible regression age 18.2 +/- 7.8 mo, 42% regression (age 20.8 
+/- 16 moBMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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of some symptoms; one had moderate sleep problems,
and one had moderate sleep problems and increased tan-
trums. These problems were generally temporary, and
resolved when treatment was stopped. On average,
according to the Parental Global Impressions, there was
little change (slight improvement) in tantrum behavior,
and slight worsening of sleep and hyperactivity, so those
are symptoms that should be documented in future treat-
ment studies and may indicate possible temporary side-
effects due to DMSA.
Note that the treatment protocol of 3 days of treatment
followed by 11 days off is much lower than that recom-
mended in the Physician Desk Reference for moderate/
severe lead poisoning (21 days of continuous treatment),
so it is expected that the treatment regimen used in this
study would have fewer side-effects than for a 21-day
treatment regimen. Overall, DMSA therapy in this study
seemed relatively safe, with only a few reports of adverse
effects that were generally temporary and of mild or mod-
erate severity.
Medical History
There was a very high correlation between "eating/licking
paint" and pica and the severity of autism (up to r = 0.63
for SAS). The strong correlation of "eating/licking paint"
and pica with urinary excretion of some metals (especially
lead, tin, thallium, antimony, and tungsten) suggests that
pica may be a significant source of toxic metals, account-
ing for up to half of the children's exposure to them. This
may be part of a vicious cycle, where a worsening of
autism leads to unusual behaviors including pica, which
in turn leads to increased consumption of toxic metals
and a worsening of symptoms.
Limitations of the Study
1) The initial 3-day round of DMSA in Phase 1 was
intended as a screening for Phase 2, but it was discov-
ered that the initial round of DMSA had a large bene-
ficial effect in dramatically improving glutathione,
and normalizing platelet levels (a marker of inflam-
mation). Thus, this study is best interpreted as a com-
parison of 1 round vs. 7 rounds of DMSA. A future
study of 1 round vs. 0 rounds would be interesting.
2) At the end of Phase 2, 80% of the children were still
excreting high amounts of lead and other toxic metals.
Thus, it appears that most of the children would need
a longer trial of DMSA to reduce their toxic metal lev-
els.
3) Most of the metals had one or more correlations
with other metals, making it difficult to distinguish
the effect of one metal from another when doing
regression analysis.
Table 14: Correlations of symptoms of "Eating/licking paint" and "pica" with symptoms of autism and urinary excretion of metals (at 
baseline or immediately after the 9th dose of DMSA in Phase 1). 
Eating/Licking Paint Pica
ATEC Total n.s. 0.33
ADOS Total 0.39 0.43
SAS 0.54 0.63
PDD-BI - modified Autism subscale 0.51 0.54
Pb-b n.s. 0.32
Pb-9 0.62 0.40
Sn-b 0.35 0.34
Tl-b 0.29 0.38
Tl-9 0.39 0.33
Sb-b 0.49 0.45
W-b 0.31 0.45
Al-9 0.38 n.s.
Correlations of symptoms were checked for all toxic metals listed in table 2, but only the significant ones (r > 0.30) are listed below.
Table 15: Correlation of initial glutathione with urinary 
excretion of toxic metals. 
Baseline 1st dose 9th dose
Cd -0.08 0.21 0.30
Al 0.17 0.21 0.29
Pb 0.20 0.18 0.25
W 0.14 -0.05 0.23
Sb 0.26 0.22 0.22
Sn -0.04 0.11 0.21
U 0.11 0.25 0.20
Tl 0.15 0.06 0.18
Bi -0.07 0.09 0.12
Ni -0.08 0.00 0.10
As 0.06 -0.04 -0.10
Hg 0.17 -0.30 -0.27
Arranged in order of degree of correlation with 9th dose.BMC Clinical Pharmacology 2009, 9:16 http://www.biomedcentral.com/1472-6904/9/16
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4) No measurement of plasma cysteine levels was con-
ducted; since each molecule of DMSA is usually
excreted in the urine bound to 2 molecules of cysteine,
it is possible that DMSA therapy may decrease cysteine
levels. However, since cysteine is a precursor of glu-
tathione, and since glutathione levels normalized after
1 round of DMSA, this may not be a problem.
5) This study was large enough for phase 1, and large
enough for phase 2 since the 1 round and 7 round
groups could be combined for a regression analysis of
changes in autism severity scores. However, a larger
study is needed in future for a true placebo-controlled,
double-blind study.
6) There was no measurement of urinary porphyrins,
a marker for heavy metal toxicity. This would be very
interesting to measure in a future study.
7) For statistical analyses involving multiple compari-
sons, care should be taken in determining which p-val-
ues are most significant. In general, for multiple
comparisons we have assumed that p < 0.01 suggests
that the results are significant.
Conclusion
1) DMSA therapy, at the dosage and frequency in this
study, is a relatively safe way to remove toxic metals,
normalize glutathione, and improve elevated platelet
levels and therefore possibly reduce inflammation in
children with autism.
2) DMSA does cause significant increased urinary loss
of potassium and chromium on the days it was taken,
so modest supplementation of chromium and potas-
sium (or increased intake of fruits and vegetables) may
be helpful.
3) One round (3 days) of DMSA was nearly as effective
as seven rounds of DMSA (3 days of DMSA, 11 days no
dosing, repeated 7 times) in improving platelet levels.
4) In 20% of the participants, 3 rounds of DMSA was
sufficient to lower excretion of toxic metals (primarily
lead), but 80% of children were still excreting high lev-
els of toxic metals (primarily lead) after 7 rounds. This
suggests that longer treatment might be useful in
reducing toxic metals in 80% of the children.
Future studies should consider longer treatment periods,
and the use of other chelators. Pre-screening for metal tox-
icity using urinary porphyrins might be useful.
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